Everything below concerns MOD GRF(1-29). We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Acute poisoning can be fatal, leading to cardiovascular collapse and death in 2–18 hours, and in general, is treated using a symptomatic and supportive approach. Diagnosis of toxicity is based on history and clinical presentation, and in general, precise plasma levels do not appear to provide useful relevant clinical information. Several levels of evidence strongly indicate diphenhydramine (similar to chlorpheniramine) can block the delayed rectifier potassium channel and, as a consequence, prolong the QT interval, leading to cardiac arrhythmias such as torsades de pointes. No specific antidote for diphenhydramine toxicity is known, but the anticholinergic syndrome has been treated with physostigmine for severe delirium or tachycardia. Benzodiazepines may be administered to decrease the likelihood of psychosis, agitation, and seizures in people who are prone to these symptoms.
12-14 August On the 12th the 1st Battalion, 7th Marines were attacked by the PAVN 8th and 9th Battalions, 90th Regiment and 1st Battalion, 368E Artillery (Rocket) Regiment in the "Arizona Territory". The Marines repelled the attack and killed 203 PAVN and captured two and 72 weapons in a daylong battle. On the 13th the Marines engaged a 100 strong PAVN force in a seven hour battle, killing 73 for the loss of five Marines killed. On the 14th the PAVN attacked again losing 13 killed and ten weapons.
== Publication == Acharya B, Acharya A, Gautam S, Ghimire SP, Mishra G, Parajuli N; et al. (2020). "Advances in diagnosis of Tuberculosis: an update into molecular diagnosis of Mycobacterium tuberculosis". Mol Biol Rep. 47 (5): 4065–4075. doi:10.1007/s11033-020-05413-7. PMID 32248381.{{cite journal}}: CS1 maint: multiple names: authors list (link) Acharya B, Meka RR, Venkatesha SH, Lees JR, Teesalu T, Moudgil KD (2020). "A novel CNS-homing peptide for targeting neuroinflammatory lesions in experimental autoimmune encephalomyelitis". Mol Cell Probes. 51 101530. doi:10.1016/j.mcp.2020.101530. PMC 7245014. PMID 32035108.{{cite journal}}: CS1 maint: multiple names: authors list (link) Meka RR, Venkatesha SH, Dudics S, Acharya B, Moudgil KD (2015). "IL-27-induced modulation of autoimmunity and its therapeutic potential". Autoimmun Rev. 14 (12): 1131–1141. doi:10.1016/j.autrev.2015.08.001. PMC 4628569. PMID 26253381.{{cite journal}}: CS1 maint: multiple names: authors list (link) Venkatesha SH, Dudics S, Acharya B, Moudgil KD (2014). "Cytokine-modulating strategies and newer cytokine targets for arthritis therapy". Int J Mol Sci. 16 (1): 887–906. doi:10.3390/ijms16010887. PMC 4307281. PMID 25561237.{{cite journal}}: CS1 maint: multiple names: authors list (link) Meka RR, Venkatesha SH, Acharya B, Moudgil KD (2019). "Peptide-targeted liposomal delivery of dexamethasone for arthritis therapy". Nanomedicine (Lond). 14 (11): 1455–1469. doi:10.2217/nnm-2018-0501. PMC 6613046.
==== Acute pain ==== Opioids are effective for the treatment of acute pain (such as pain following surgery). For immediate relief of moderate to severe acute pain, opioids are frequently the treatment of choice due to their rapid onset, efficacy and reduced risk of dependence. However, a 2018 report showed a clear risk of prolonged opioid use when opioid analgesics are initiated for an acute pain management following surgery or trauma. They have also been found to be important in palliative care to help with the severe, chronic, disabling pain that may occur in some terminal conditions such as cancer, and degenerative conditions such as rheumatoid arthritis. In many cases opioids are a successful long-term care strategy for those with chronic cancer pain. Just over half of all states in the U.S. have enacted laws to restrict prescribing or dispensing opioids for acute pain.
Sources: en.wikipedia.org
=== RAID-FN Inventory === The Ro-Allison-Indiana-Dhurandhar Food Noise Inventory (RAID-FN Inventory) consists of seven items in the short-form version and 23 items in the long-form version. Both versions of the questionnaire capture three distinct factors of food noise: preoccupation with food, persistence of thoughts, and dysphoria arising from those thoughts. A reliability test conducted by the scale’s developers indicated that the food noise construct is likely stable (that is, a trait), although the dysphoric aspect may be a temporary state. Unlike the Food Noise Questionnaire (FNQ), no difference in the level of food noise experienced by men versus women was found using the RAID-FN Inventory. The researchers who developed the RAID-FN Inventory noted that further validation of the tool involving in-person, in-clinic studies is required. Additionally, they suggested that future studies might investigate how the inventory responds to changes in food noise arising from the environment or therapeutic interventions. The direct-to-patient healthcare company Ro provided funding for the RAID-FN Inventory’s development; however, the company had no control over the tool’s creation or the authorship of the validation study.
While dichloroacetylene is nephrotoxic in rats, its nephrotoxicity in humans is not well-understood. Dichloroacetylene has mutagenic effects on Salmonella typhimurium. Like trichloroethylene, dichloroacetylene is metabolized to S-(1,2-dichlorovinyl)-L-cysteine (DCVC) in vivo. The maximum safe concentration of dichloroacetylene in air is 0.1 parts per million. It is unsafe to store dichloroacetylene in close proximity to potassium, sodium, or aluminium powder. According to the Department of Transportation, it is forbidden to ship dichloroacetylene.
From the mid-1980s onward, the media reported "roid rage" as a side effect of AAS. A 2005 review determined that some, but not all, randomized controlled studies have found that AAS use correlates with hypomania and increased aggressiveness, but pointed out that attempts to determine whether AAS use triggers violent behavior have failed, primarily because of high rates of non-participation. A 2008 study on a nationally representative sample of young adult males in the United States found an association between lifetime and past-year self-reported AAS use and involvement in violent acts. Compared with individuals that did not use steroids, young adult males that used AAS reported greater involvement in violent behaviors even after controlling for the effects of key demographic variables, previous violent behavior, and polydrug use. A 1996 review examining the blind studies available at that time also found that these had demonstrated a link between aggression and steroid use, but pointed out that with estimates of over one million past or current steroid users in the United States at that time, an extremely small percentage of those using steroids appear to have experienced mental disturbance severe enough to result in clinical treatments or medical case reports. The relationship between AAS use and depression is inconclusive. A 1992 review found that AAS may both relieve and cause depression, and that cessation or diminished use of AAS may also result in depression, but called for additional studies due to disparate data.
Robinson ran for a third time for Oregon's 4th congressional district in 2014. He was unopposed in the Republican primary and faced another rematch in the general election with DeFazio, who was unopposed in the Democratic primary. Robinson lost the election with 116,534 votes to DeFazio's 181,624.
Flupentixol (INN), also known as flupenthixol (former BAN), marketed under brand names such as Depixol and Fluanxol is a typical antipsychotic drug of the thioxanthene class. It was introduced in 1965 by Lundbeck. In addition to single drug preparations, it is also available as flupentixol/melitracen—a combination product containing both melitracen (a tricyclic antidepressant) and flupentixol (marketed as Deanxit). It is approved for use in the UK, Australia, Canada, Russian Federation, South Africa, New Zealand, Philippines, Iran, Germany, among others. Flupentixol is not approved for use in the United States.
Sources: en.wikipedia.org
Small-cell carcinoma is a type of highly aggressive cancer that most commonly arises within the lungs, but can also occasionally arise in the cervix, prostate, bladder, and gastrointestinal tract. Compared to non-small cell carcinoma, small cell carcinoma is more aggressive, with a shorter doubling time, higher growth fraction, and earlier development of metastases. Small-cell carcinoma is a neuroendocrine tumor, meaning that the cells were originally part of the neuroendocrine system. As a result, small cell carcinomas often secrete various hormones, such as adrenocorticotropic hormone or vasopressin. The unpredictable hormone secretion of small-cell carcinoma adds additional symptoms and mortality to the aggressive course of the cancer. Extensive stage small cell lung cancer (SCLC) is classified as a rare disorder. Ten-year relative survival rate (combined limited and extensive SCLC) is 3.5% (4.3% for women, 2.8% for men). Survival can be higher or lower based on a combination of factors including stage, age, sex and race. While most lung cancers are associated with tobacco smoking, SCLC is very strongly associated with tobacco smoking.
According to author Mark Cartwright, "Inca roads covered over 40,000 km (25,000 miles), principally in two main highways running north to south across the Inca Empire, which eventually spread over ancient Peru, Ecuador, Chile and Bolivia." Several sources challenge Cartwright's claim in stating that the Inca roads covered either more or less area then he describes. This number is difficult to solidify since some of the pathways of the Inca still may remain unaccounted for, being that they may have been washed away or covered by natural forces. "Inca engineers were also undaunted by geographical difficulties and built roads across ravines, rivers, deserts, and mountain passes up to 5,000 meters high." Many of the constructed roads are not uniform in design. Most of the uncovered roads are about one to four meters wide. Although this is true, some roads, such as the highway in Huanuco Pampa province, can be much larger. As mentioned in the Pathway systems section, the Inca people mainly traveled on foot. Knowing this, the roads created were most likely built and paved for both humans and animals to walk and/or run along. Several roads were paved with stones or cobbles and some were "edged and protected with the use of small stone walls, stone markers, wooden or cane posts, or piles of stones." Drainage was something that was of particular interest and importance to the Inca people. Drains and culverts were built to ensure that rainwater would effectively run off of the road's surface.
In 1882, Lord Rayleigh theoretically estimated the maximum amount of charge a liquid droplet could carry before throwing out fine jets of liquid. This is now known as the Rayleigh limit. In 1914, John Zeleny published work on the behaviour of fluid droplets at the end of glass capillaries and presented evidence for different electrospray modes. Wilson and Taylor and Nolan investigated electrospray in the 1920s and Macky in 1931. The electrospray cone (now known as the Taylor cone) was described by Sir Geoffrey Ingram Taylor. The first use of electrospray ionization with mass spectrometry was reported by Malcolm Dole in 1968. John Bennett Fenn was awarded the 2002 Nobel Prize in Chemistry for the development of electrospray ionization mass spectrometry in the late 1980s.
However, he also observed that many other sports exhibit the same coercive structure, including boxing and MMA. Writing in Performance Enhancement & Health in 2024, Dr. Andrew Richardson noted that while the international sporting community responded strongly to the Enhanced Games, academic literature has been more "tempered." Richardson said that the format could represent a shift in sports physiology research and suggested it might reduce social stigma for individuals disclosing performance-enhancing substance use. He further noted that some scholars have cautiously welcomed the concept, provided specific ethical and safety caveats are addressed.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.